Vivani Medical Confirms Mid-2026 SLIM-1 Trial Start, Secures $9.7M Q1 Financing
VANI sits 26% above its 52-week low of $0.923.
Summary
Vivani Medical reported its first-quarter 2026 financial results, detailing a net loss of $6.8 million and cash used in operations of $6.2 million. Critically, the company secured $9.7 million in financing activities during the quarter, contributing to a total of $28 million in cash and commitments, which is expected to fund operations through the first half of 2027. This financial update reinforces the cash runway previously outlined in the 10-K. The company also provided a significant business update, confirming that the initiation of its SLIM-1™ Phase 1 clinical trial for its semaglutide implant (NPM-139) is on track for mid-2026, with top-line results anticipated by year-end. Furthermore, Vivani Medical is actively exploring options for its wholly-owned subsidiary, Cortigent Inc., to become an independent, publicly traded company, with an S-1 amendment recently filed. These updates are material for a clinical-stage biopharmaceutical company, providing clarity on its financial stability and progress on its lead product candidate, while also signaling potential value creation through the Cortigent spin-off. Investors will be watching for the SLIM-1 trial initiation, top-line results by year-end, and further developments regarding Cortigent's separation.
At the time of this announcement, VANI was trading at $1.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $98.2M. The 52-week trading range was $0.92 to $1.92. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.